Last updated: August 2, 2026
Tranxene is the U.S. brand name for clorazepate dipotassium, a benzodiazepine approved for anxiety disorders, acute alcohol withdrawal, and adjunctive treatment of partial seizures. Its commercial profile is mature and largely genericized. No material U.S. patent or regulatory exclusivity protects the product, and publicly available filings do not report Tranxene-specific revenue. The economic outlook is therefore driven by prescription retention, generic substitution, controlled-substance regulation, supply continuity, and the size of the declining benzodiazepine market rather than by patent protection.
What is Tranxene and how is clorazepate dipotassium used?
Tranxene contains clorazepate dipotassium, a prodrug that is converted to desmethyldiazepam, also known as nordiazepam. It is an oral benzodiazepine supplied in tablet form.
| Attribute |
Tranxene profile |
| Brand |
Tranxene and Tranxene T-Tab |
| Active ingredient |
Clorazepate dipotassium |
| Drug class |
Benzodiazepine |
| U.S. regulatory status |
Prescription drug; Schedule IV controlled substance |
| Dosage form |
Oral tablets |
| Approved uses |
Anxiety disorders, acute alcohol withdrawal, adjunctive therapy for partial seizures |
| Original U.S. approval |
1970s |
| Current market structure |
Brand plus multiple generic clorazepate products |
| Patent position |
No meaningful remaining market exclusivity identified in the FDA public product record |
| Primary commercial risk |
Generic substitution and declining benzodiazepine utilization |
The product has a long half-life through its active metabolite. That pharmacology supports less frequent administration than some shorter-acting benzodiazepines but also increases concerns about accumulation, sedation, impaired psychomotor function, dependence, withdrawal, and use in older patients.
What is the FDA regulatory status of Tranxene?
Tranxene is an approved prescription benzodiazepine, not an over-the-counter product. The FDA-approved labeling identifies clorazepate dipotassium for anxiety, acute alcohol withdrawal, and adjunctive management of partial seizures. The product carries controlled-substance restrictions and boxed-warning language addressing abuse, misuse, addiction, physical dependence, and withdrawal reactions.[1]
The key FDA milestones are:
| Regulatory event |
Status |
| Original NDA approval |
Historical approval; Drugs@FDA identifies Tranxene as an approved clorazepate product |
| Current legal category |
Schedule IV under the Controlled Substances Act |
| Prescription status |
Prescription only |
| Generic approvals |
Multiple abbreviated new drug applications have been approved for clorazepate dipotassium tablets |
| REMS |
No product-specific REMS comparable to opioid Risk Evaluation and Mitigation Strategies has been identified |
| Label risk controls |
Boxed warning and class-wide benzodiazepine safety warnings |
FDA labeling changes in recent years have increased emphasis on abuse, misuse, addiction, dependence, and withdrawal. Those warnings apply to Tranxene and its generic equivalents.[1,2]
What patents protect Tranxene and clorazepate dipotassium?
No active patent estate appears to provide meaningful exclusivity for Tranxene in the United States. The original product was approved decades before the modern Hatch-Waxman environment, and any historical composition, formulation, or use patents associated with the product would have expired long ago.
The current commercial position is consistent with a fully mature small-molecule product:
| Patent category |
Tranxene status |
| Active ingredient patent |
Expired |
| Original formulation patent |
Expired or no longer commercially relevant |
| Method-of-use patent |
No material active exclusivity identified |
| Orange Book-listed patent |
No meaningful current patent barrier identified |
| Pediatric exclusivity |
Not commercially relevant |
| New chemical entity exclusivity |
Expired decades ago |
| Generic approval barrier |
None based on patent exclusivity |
The FDA Orange Book is the principal source for patents and regulatory exclusivity associated with approved small-molecule products. Public product records for clorazepate do not indicate an active patent position capable of delaying routine generic approval.[3]
When did Tranxene lose exclusivity?
Tranxene lost meaningful market exclusivity many years ago. The active pharmaceutical ingredient, clorazepate dipotassium, is an established benzodiazepine with generic products marketed in the United States for decades.
The commercial effect is direct:
- Generic manufacturers can submit ANDAs.
- Approved generics can use the reference product’s safety and efficacy findings through the abbreviated pathway.
- Pharmacy-level substitution can shift prescriptions away from the brand.
- The brand must compete through availability, contracting, physician familiarity, or patient continuity rather than patent protection.
Because exclusivity expired before current commercial reporting practices became standard, public sources do not provide a reliable, product-level historical revenue series for Tranxene.
What is the Orange Book status of Tranxene?
Tranxene is an approved reference product with generic competition. The Orange Book framework does not create an ongoing barrier to ANDA approvals where no unexpired listed patent or regulatory exclusivity remains.
The practical Orange Book assessment is:
- Tranxene has reference-drug status for approved clorazepate products.
- Generic clorazepate products can compete on an abbreviated basis.
- No current Orange Book patent listing appears to support a Paragraph IV litigation strategy against generic entry.
- Any future market protection would require a new patentable product, such as a differentiated formulation or delivery system, and would not automatically protect legacy Tranxene tablets.
How many patents cover Tranxene?
No active, commercially significant U.S. patents have been identified as covering the marketed Tranxene tablet. Historical patents may appear in archival patent records, but they do not provide present-day exclusivity.
The relevant distinction is between historical patent ownership and enforceable market protection. Tranxene’s current value is not supported by an active patent portfolio. A search for the brand, active ingredient, and FDA reference-product record is more relevant than an ownership search alone because legacy patents may have expired, been abandoned, or become commercially irrelevant.
Which companies compete with Tranxene?
Tranxene competes with generic clorazepate suppliers and with other benzodiazepines. The principal competitive products include diazepam, lorazepam, alprazolam, clonazepam, and chlordiazepoxide.
| Competitor group |
Examples |
Competitive effect |
| Generic clorazepate |
Multiple ANDA-approved tablet products |
Direct substitution and price pressure |
| Long-acting benzodiazepines |
Diazepam, clonazepam |
Compete in anxiety, seizure, and withdrawal treatment |
| Intermediate-acting benzodiazepines |
Lorazepam |
Compete in anxiety and alcohol withdrawal |
| Shorter-acting benzodiazepines |
Alprazolam |
Compete in anxiety and panic disorder |
| Non-benzodiazepine therapies |
SSRIs, SNRIs, anticonvulsants, behavioral therapy |
Reduce chronic benzodiazepine demand |
Tranxene’s long-acting pharmacology may retain clinical relevance in selected patients, but it does not create commercial differentiation strong enough to overcome generic pricing and broad therapeutic substitution.
What formulation patents protect Tranxene?
The marketed Tranxene product is an oral tablet. No current formulation patent has been identified that provides meaningful exclusivity for the legacy product.
A new commercial strategy would require a differentiated product, such as:
- Modified-release clorazepate
- A lower-dose titration formulation
- An orally disintegrating tablet
- A liquid or patient-specific dosing presentation
- A combination product
- A delivery system designed to reduce misuse or improve adherence
Each approach would require separate FDA development and patent analysis. A reformulated product could obtain patents, but those rights would protect the new formulation rather than the existing Tranxene tablet. FDA approval would also require adequate chemistry, manufacturing, controls, stability, bioequivalence or clinical evidence, and labeling support.
What method-of-use patents cover clorazepate?
No active method-of-use position has been identified that materially restricts generic clorazepate use in the approved indications.
The legacy indications are established uses:
- Anxiety disorders
- Acute alcohol withdrawal
- Adjunctive treatment of partial seizures
Method-of-use patents for these indications would face major patentability and enforceability challenges because the clinical uses and active ingredient are longstanding. A new indication could create a patent opportunity only if supported by a novel, non-obvious clinical finding and an FDA-approved or medically supportable labeling strategy.
Are generic manufacturers challenging Tranxene through Paragraph IV filings?
No material, current Paragraph IV dispute involving Tranxene has been identified. The likely reason is economic and legal: the product has no apparent active patent barrier worth challenging.
Paragraph IV litigation is most relevant when a listed patent could delay generic launch. For Tranxene, the commercial pathway is already genericized. ANDA applicants therefore have little reason to litigate over legacy patents that are expired or absent from the current Orange Book record.
The main generic risks are not litigation risks. They are:
- Low-cost competition
- Multiple suppliers
- Pharmacy substitution
- Contracting pressure
- Potential product discontinuations
- Manufacturing or raw-material shortages
What patent litigation affects Tranxene?
No significant active U.S. patent litigation involving Tranxene or clorazepate dipotassium has been identified as a determinant of market access.
Any litigation exposure is more likely to concern:
- Product liability
- Controlled-substance prescribing
- Failure-to-warn allegations
- Manufacturing quality
- Distribution controls
- Pharmacy or wholesaler conduct
Those matters can affect a brand owner’s cost base and reputation but do not restore product exclusivity.
What is Tranxene’s financial trajectory?
Public company filings do not separately disclose Tranxene revenue, gross margin, prescription volume, or operating profit. The product is generally reported within broader pharmaceutical portfolios, if reported at all. A precise Tranxene revenue forecast cannot be derived from audited financial statements.
The financial trajectory can still be characterized:
| Period |
Likely economic profile |
| Launch and protected period |
Higher pricing and brand-driven demand |
| Early generic period |
Rapid price erosion and prescription substitution |
| Mature generic period |
Low revenue per prescription; volume and supply continuity become decisive |
| Current period |
Niche brand economics with limited pricing power and no patent support |
For a brand owner, Tranxene is likely a portfolio-maintenance product rather than a growth asset. Revenue depends on residual branded demand, payer coverage, distributor inventory, and the ability to maintain supply. Gross margins may remain positive if manufacturing costs are low, but revenue upside is constrained by generic competition and clinical substitution.
For generic manufacturers, the product can remain commercially viable if the supplier has:
- Reliable active-ingredient sourcing
- Low manufacturing costs
- Consistent FDA compliance
- Stable wholesaler relationships
- Limited competition in a particular strength
The market is vulnerable to a low-volume, multi-supplier equilibrium. If several manufacturers exit, temporary pricing or supply pressure could emerge, but that would not create durable patent-based value.
How do benzodiazepine safety policies affect Tranxene demand?
Regulatory and clinical policy trends are unfavorable to chronic benzodiazepine growth. FDA labeling emphasizes dependence and withdrawal. Prescribers also face increasing scrutiny over co-prescribing benzodiazepines with opioids and other central nervous system depressants.[1,2]
Demand pressure comes from:
- Older-patient safety concerns
- Fall and cognitive-impairment risk
- Dependence and withdrawal management
- Opioid-benzodiazepine interaction concerns
- Preference for non-benzodiazepine anxiety treatment
- Behavioral-health treatment expansion
- State-level controlled-substance monitoring
These pressures are partly offset by continuing use in acute alcohol withdrawal, seizure adjunctive therapy, severe anxiety, and patients who remain stable on long-term treatment.
What generic launch scenarios exist for Tranxene?
Because generic clorazepate is already marketed, the relevant scenarios concern competitive intensity rather than first generic entry.
Base case: continued erosion
The brand retains a small niche while generic products capture most prescriptions. Prices remain constrained, and the product contributes limited portfolio revenue.
Downside case: brand withdrawal
The branded product is discontinued or commercially deprioritized. Patients and prescribers transition to generic clorazepate or alternative benzodiazepines.
Supply-disruption case
One or more generic manufacturers exit. Short-term shortages or allocation issues increase the value of remaining suppliers, but the effect is operational rather than patent-driven.
Reformulation case
A manufacturer develops a differentiated clorazepate formulation. This could create a new patent and pricing opportunity, but it would require new development investment and would face substitution risk from inexpensive tablets.
What geographic coverage does Tranxene have?
The strongest commercial relevance is in the United States, where Tranxene is an established brand and clorazepate is available as a generic prescription product. International availability varies by country, and the brand name, marketing authorization holder, controlled-substance classification, and generic status may differ.
Geographic value is limited by:
- Benzodiazepine prescribing restrictions
- National reimbursement policies
- Local generic competition
- Controlled-substance import and distribution rules
- Country-specific regulatory approvals
- Different treatment guidelines for anxiety, seizures, and alcohol withdrawal
No broad international patent moat should be assumed for clorazepate. Any country-specific patent or regulatory right would require separate confirmation through the relevant national register.
How strong is the Tranxene patent estate?
Tranxene has a weak patent estate by current pharmaceutical standards. Its value is based on legacy approval, clinical familiarity, and manufacturing continuity rather than enforceable intellectual property.
| Patent-strength factor |
Assessment |
| Composition-of-matter protection |
Expired |
| Formulation protection |
No meaningful active protection identified |
| Method-of-use protection |
No material active protection identified |
| Orange Book leverage |
Minimal |
| Paragraph IV deterrence |
Minimal |
| Freedom to manufacture generic tablets |
Broad, subject to ordinary FDA requirements |
| Lifecycle-management potential |
Possible only through a new product or indication |
What licensing deals involve Tranxene?
No major recent licensing transaction centered on Tranxene has been identified in public company disclosures. The product has more likely moved through portfolio acquisitions, product transfers, or legacy commercialization arrangements than through a high-value innovation license.
A licensing transaction would be commercially rational only under limited conditions:
- The buyer has a low-cost supply chain.
- The product fills a controlled-substance portfolio gap.
- The target has stable institutional or specialty demand.
- The transaction includes related benzodiazepine products.
- The seller wants to exit low-growth assets.
A standalone Tranxene transaction would likely command a modest valuation relative to protected branded pharmaceuticals because revenue is not supported by exclusivity.
Key Takeaways
- Tranxene is clorazepate dipotassium, an established Schedule IV benzodiazepine.
- U.S. exclusivity expired decades ago.
- No meaningful active Orange Book patent barrier or Paragraph IV litigation position has been identified.
- Generic clorazepate is the principal commercial competitor.
- Public filings do not disclose product-level Tranxene revenue, so an audited financial trajectory cannot be calculated.
- Brand economics are likely mature, low-growth, and dependent on residual demand and supply continuity.
- Long-term benzodiazepine safety concerns create structural demand pressure.
- The main commercial opportunity is in reliable generic manufacturing or a separately patented reformulation, not in the legacy tablet.
- No major current licensing or patent-litigation event appears to affect market access.
FAQs
Is Tranxene still available in the United States?
Tranxene has an established U.S. regulatory record, while generic clorazepate dipotassium products provide the principal source of market supply. Brand availability can vary by manufacturer, wholesaler inventory, and pharmacy purchasing decisions.
Is clorazepate the same as Tranxene?
Yes. Tranxene is the brand name, and clorazepate dipotassium is its active pharmaceutical ingredient. Generic clorazepate products are intended to be therapeutically equivalent to the approved reference product.
Can a generic company launch Tranxene without a patent settlement?
Yes. Where no unexpired listed patent or regulatory exclusivity blocks approval, a generic company can obtain FDA approval through the ANDA pathway without a Paragraph IV settlement.
Does Tranxene have a biosimilar risk?
No. Tranxene is a chemically synthesized small-molecule drug, not a biologic. Its competitive risk comes from generic drugs, not biosimilars.
Could a new clorazepate formulation receive patent protection?
Potentially. A novel formulation, delivery system, dosing regimen, or new clinical use could support patent claims if it satisfies statutory patentability requirements. Such rights would protect the new product rather than restore exclusivity for the legacy Tranxene tablet.
References
- U.S. Food and Drug Administration. (2020). FDA requiring boxed warning updated to improve safe use of benzodiazepine drug class. https://www.fda.gov
- U.S. Food and Drug Administration. (2024). Clorazepate dipotassium prescribing information. https://www.accessdata.fda.gov
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov
- U.S. Drug Enforcement Administration. (2024). Drug scheduling. https://www.dea.gov
- Recordati Rare Diseases Inc. (2024). Tranxene product information and prescribing information. https://www.recordatirarediseases.com
